DTB No 3. Mirabegron, Betmiga® for overactive bladder syndrome

Content tools

Share it

Irrelevant benefits

Mirabegron is the first selective beta 3 adrenergic receptor agonist.
Its efficacy is similar to that of anticholinergic drugs. There is a high response to placebo. The absolute improvement with mirabegron is very small and clinically irrelevant.
It produces less dry mouth syndrome than tolterodine but there are no differences in treatment withdrawal due to adverse effects. Tachycardia and urinary infections are the most frequent adverse effects. Its long-term safety profile is unknown.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *